Anti-polyethyleneglycol antibody response to PEGylated substances

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 889-891

  Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anti polyethyleneglycol antibody response; Liposome; Nanocarrier; PEGylation; Polyethyleneglycol; Protein

Indexed keywords

BOVINE SERUM ALBUMIN; DOXORUBICIN; LIPOSOME; MACROGOL; OVALBUMIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; DRUG DELIVERY SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION;

ANIMALS; DRUG CARRIERS; HUMANS; IMMUNOGLOBULIN M; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 84878821055     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00107     Document Type: Article

References (36)

1. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev., 54, 459-476 (2002).
2. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem., 6, 150-165 (1995).
3. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214-221 (2003).
4. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55, 1261-1277 (2003).
5. Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res., 63, 8377-8383 (2003).
6. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today, 10, 1451-1458 (2005).
7. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol., 31 (Suppl 13), 36-52 (2004).
8. Armstrong JK. PEGylated protein drugs. (Veronese FM ed.) Birkhauser Verlag, Basel (2009).
9. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol., 74, 36-39 (1984).
10. Constantinou A, Chen C, Deonarain MP. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol. Lett., 32, 609-622 (2010).
11. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 30, 351-367 (2006).
12. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 252, 3582-3586 (1977).
13. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem., 252, 3578-3581 (1977).
14. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol. J., 5, 113-128 (2010).
15. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol., 70, 124-131 (1983).
16. Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol. Pharm. Bull., 35, 1336-1342 (2012).
17. Caliceti P, Schiavon O, Veronese FM. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug. Chem., 12, 515-522 (2001).
18. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther., 8, R12 (2006).
19. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 110, 103-111 (2007).
20. Hu X, Olivier K, Polack E, Crossman M, Zokowski K, Gronke RS, Parker S, Li Z, Nestorov I, Baker DP, Clarke J, Subramanyam M. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J. Pharmacol. Exp. Ther., 338, 984-996 (2011).
21. Tillmann H, Ganson NJ, Patel K, Thompson AJ, Abdelmalek M, Moody T, McHutchison JG, Hershfield MS. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hapatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J. Hepatol., 52 (Suppl. 1), S129 (2010).
22. Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int. J. Immunopharmacol., 7, 725-730 (1985).
23. Zhang C, Fan K, Ma X, Wei D. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PLoS ONE, 7, e39659 (2012).
24. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 292, 1071-1079 (2000).
25. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release, 88, 35-42 (2003).
26. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release, 115, 243-250 (2006).
27. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release, 112, 15-25 (2006).
28. Kaminskas LM, McLeod VM, Porter CJ, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci., 100, 5069-5077 (2011).
29. Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, Oku N. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles. Int. J. Pharm., 432, 75-79 (2012).
30. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, Maeda T, Yamakawa N, Okamoto Y, Otsuka M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res., 26, 2270-2279 (2009).
31. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of PEGylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur. J. Cancer, 42, 882-887 (2006).
32. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 298, 607-612 (2001).
33. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J. Control. Release, 115, 251-258 (2006).
34. Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, Ishihara H, Kikuchi H. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int. J. Pharm., 436, 636-643 (2012).
35. La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC. Factors affecting the pharmacokinetics of PEGylated liposomal doxorubicin in patients. Cancer Chemother. Pharmacol., 69, 43-50 (2012).
36. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of PEGylated liposomal doxorubicin. Cancer Chemother. Pharmacol., 61, 695-702 (2008).